Clinical Trials
13 trialsNCT06877676 2026-04-13
Pre-Approval Expanded Access Study for TAR-200 Treating Physician Use
Janssen Research & Development, LLC
Approved for marketing
NCT04507503 2026-03-10
Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
Taiho Oncology, Inc.
Approved for marketing
NCT05757973 2025-12-09
Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Approved for marketing
NCT06132191 2025-11-20
Expanded Access Use of Cemiplimab in Patients With Solid Tumors
Regeneron Pharmaceuticals
Approved for marketing
NCT05164250 2025-11-10
Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)
Regeneron Pharmaceuticals
Approved for marketing
NCT05162443 2025-08-26
Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation
Bristol-Myers Squibb
Approved for marketing
NCT04617002 2025-08-20
Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas
Jazz Pharmaceuticals
Approved for marketing
NCT06279728 2025-07-03
Medical Access Program for Datopotamab Deruxtecan in EGFRm NSCLC Patients
Daiichi Sankyo
Approved for marketing
NCT04220203 2025-06-26
Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer
Seagen Inc.
Approved for marketing
NCT05463939 2025-06-15
Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients
Janssen Research & Development, LLC
Approved for marketing
NCT03825484 2025-06-13
Expanded Access Program (EAP) for Participants With Advanced Cancers and Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations Who Have Exhausted All Treatment Options
Janssen Scientific Affairs, LLC
Approved for marketing
NCT04599712 2025-06-13
Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer
Janssen Research & Development, LLC
Approved for marketing
NCT05401214 2025-06-13
Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination)
Janssen Research & Development, LLC
Approved for marketing